.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Citi
Accenture
QuintilesIMS
Queensland Health
Cipla
Chinese Patent Office
Moodys
Fish and Richardson
Merck

Generated: June 26, 2017

DrugPatentWatch Database Preview

NUPLAZID Drug Profile

« Back to Dashboard

Which patents cover Nuplazid, and when can generic versions of Nuplazid launch?

Nuplazid is a drug marketed by Acadia Pharms Inc and is included in one NDA. There are thirteen patents protecting this drug.

This drug has one hundred and twenty-nine patent family members in twenty-seven countries.

The generic ingredient in NUPLAZID is pimavanserin tartrate. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.

Summary for Tradename: NUPLAZID

Patents:13
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Drug Prices:see details
DailyMed Link:NUPLAZID at DailyMed

Pharmacology for Tradename: NUPLAZID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes9,296,694► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes7,858,789► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes7,732,615► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes8,921,393► Subscribe ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes7,115,634► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: NUPLAZID

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,713,995Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
7,994,193Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
8,236,960Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms► Subscribe
2,017,165,273► Subscribe
7,393,861Derivatives of 4-aminopiperidine and their use as a medicament► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NUPLAZID

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2007133802► Subscribe
Slovenia2009000► Subscribe
Australia2008254238► Subscribe
World Intellectual Property Organization (WIPO)0166521► Subscribe
Slovenia1587789► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Fuji
Colorcon
Healthtrust
Cantor Fitzgerald
Johnson and Johnson
Dow
Covington
Mallinckrodt
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot